PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022

Description:

PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022

Summary

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

Highlights

Key Questions Answered

- What environmental factors limit the uptake of current HPV vaccines?
- What opportunities exist to overcome these environmental factors?
- What are the main unmet needs of current HPV vaccines?
- What technologies are positioned to address these unmet needs?
- What opportunities will remain for the development of new HPV vaccines?
- What environmental factors will influence the introduction of novel HPV vaccines?

Key Findings

- New nine-valent HPV vaccines are expected to be widely adopted following market approval, stealing market share from existing vaccines. Though a high price represents a potential barrier to market access.
- Significant environmental barriers to HPV vaccination exist, which currently serve to limit vaccine uptake.
- The emphasis of HPV vaccination is shifting away from an initial focus on cervical cancer prevention in females, towards prevention of a range of cancers in both males and females.
- The inclusion of males in routine HPV vaccine recommendations will expand the size of the HPV vaccines market

Scope

- Overview of the latest advances in prophylactic vaccination.
- Analysis of the future potential for novel and existing HPV vaccines.
- Key topics covered include unmet needs, opportunities, and drivers and barriers specific to prophylactic HPV vaccines.

Reasons to buy

- Understand the dynamics of the prophylactic HPV vaccines market, and the unique barriers to market access.
- Identify opportunities for the development and delivery of HPV vaccines, and to identify emerging players with potentially strong product portfolios.
- Develop business strategies by understanding the trends shaping and driving the future of prophylactic HPV vaccination.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Gain insight on the challenges associated with delivering prophylactic HPV vaccines and the impact of novel
- Track vaccine sales in the global HPV vaccines market from 2012-2022
6.2 Protection against Multiple HPV Types
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Vaccine Coverage Rates
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Perception of Vaccine Safety
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Awareness of HPV Vaccination
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 Affordability of HPV Vaccines
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
6.7 Coverage of HPV Types Prevalent in Certain Populations
6.7.1 Unmet Need
6.7.2 Gap Analysis
6.7.3 Opportunity
6.8 Vaccine Compliance Rates
6.8.1 Unmet Need
6.8.2 Gap Analysis
6.8.3 Opportunity
6.9 Lifelong Protection from HPV Infection Not Established
6.9.1 Unmet Need
6.9.2 Gap Analysis
6.9.3 Opportunity
6.10 Ongoing Need for Cervical Cancer Screening
6.10.1 Unmet Need
6.10.2 Gap Analysis
6.10.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.2 Clinical Trial Mapping
7.2.1 Clinical Trials by Country
7.2.2 Clinical Trials by Phase and Trial Status
7.3 Promising Vaccines in Clinical Development
7.3.1 V503
7.3.2 Xiamen Innovax (Bivalent Vaccine)
7.4 Innovative HPV Vaccines in Early Development
7.4.1 Low-Cost HPV Vaccines
7.4.2 Universal HPV Vaccines
8 Current and Future Players
8.1 Overview
8.2 Trends in Corporate Strategy
8.3 Company Profiles
8.3.1 Merck
8.3.2 GSK
9 Market Outlook
9.1 Global Markets
9.1.1 Forecast
9.1.2 Drivers and Barriers - Global Issues
9.2 US
9.2.1 Forecast
9.2.2 Key Events
9.2.3 Drivers and Barriers
9.3 France
9.3.1 Forecast
<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>Gardasil SWOT Analysis, 2014</td>
</tr>
<tr>
<td>13</td>
<td>Global Sales Forecasts ($m) for Gardasil, 2012-2022</td>
</tr>
<tr>
<td>14</td>
<td>Product Profile - Cervarix</td>
</tr>
<tr>
<td>15</td>
<td>Phase III Efficacy Trials - Cervarix</td>
</tr>
<tr>
<td>16</td>
<td>Safety Profile - Cervarix</td>
</tr>
<tr>
<td>17</td>
<td>Cervarix SWOT Analysis, 2014</td>
</tr>
<tr>
<td>18</td>
<td>Global Sales Forecasts ($m) for Cervarix, 2012-2022</td>
</tr>
<tr>
<td>19</td>
<td>Overall Unmet Needs - Current and Future Level of Attainment</td>
</tr>
<tr>
<td>20</td>
<td>HPV Vaccines - Clinical Trials by Phase and Status, 2014</td>
</tr>
<tr>
<td>21</td>
<td>HPV Vaccines - Phase Pipeline, 2014</td>
</tr>
<tr>
<td>22</td>
<td>Product Profile - V503</td>
</tr>
<tr>
<td>23</td>
<td>V503 SWOT Analysis, 2013</td>
</tr>
<tr>
<td>24</td>
<td>Global Sales Forecasts ($m) for V503, 2012-2022</td>
</tr>
<tr>
<td>25</td>
<td>Bivalent Vaccine (Xiamen Innovax) SWOT Analysis, 2014</td>
</tr>
<tr>
<td>26</td>
<td>Key Companies in the HPV Vaccine Market, 2014</td>
</tr>
<tr>
<td>27</td>
<td>Merck's HPV Vaccine Portfolio Assessment, 2014</td>
</tr>
<tr>
<td>28</td>
<td>Merck SWOT Analysis, 2014</td>
</tr>
<tr>
<td>29</td>
<td>GSK's HPV Vaccine Portfolio Assessment, 2014</td>
</tr>
<tr>
<td>30</td>
<td>GSK SWOT Analysis, 2014</td>
</tr>
<tr>
<td>31</td>
<td>Global Sales Forecasts ($m) for HPV Vaccines, 2012-2022</td>
</tr>
<tr>
<td>32</td>
<td>Global HPV Vaccine Market - Drivers and Barriers, 2014</td>
</tr>
<tr>
<td>33</td>
<td>Sales Forecasts ($m) for HPV Vaccines in the United States, 2012-2022</td>
</tr>
<tr>
<td>34</td>
<td>Key Events Impacting Sales for HPV Vaccines in the United States, 2012-2022</td>
</tr>
<tr>
<td>35</td>
<td>United States HPV Vaccine Market - Drivers and Barriers, 2014</td>
</tr>
<tr>
<td>36</td>
<td>Sales Forecasts ($m) for HPV Vaccines in France, 2012-2022</td>
</tr>
<tr>
<td>37</td>
<td>Key Events Impacting Sales for HPV Vaccines in France, 2012-2022</td>
</tr>
<tr>
<td>38</td>
<td>France HPV Vaccine Market - Drivers and Barriers, 2014</td>
</tr>
<tr>
<td>39</td>
<td>Sales Forecasts ($m) for HPV Vaccines in Germany, 2012-2022</td>
</tr>
<tr>
<td>40</td>
<td>Key Events Impacting Sales for HPV Vaccines in Germany, 2014</td>
</tr>
<tr>
<td>41</td>
<td>Germany HPV Vaccine Market - Drivers and Barriers, 2014</td>
</tr>
<tr>
<td>42</td>
<td>Sales Forecasts ($m) for HPV Vaccines in Italy, 2012-2022</td>
</tr>
<tr>
<td>43</td>
<td>Key Events Impacting Sales for HPV Vaccines in Italy, 2014</td>
</tr>
<tr>
<td>44</td>
<td>Italy HPV Vaccine Market - Drivers and Barriers, 2014</td>
</tr>
<tr>
<td>45</td>
<td>Sales Forecasts ($m) for HPV Vaccines in Spain, 2012-2022</td>
</tr>
<tr>
<td>46</td>
<td>Key Events Impacting Sales for HPV Vaccines in Spain, 2012-2022</td>
</tr>
<tr>
<td>47</td>
<td>Spain HPV Vaccine Market - Drivers and Barriers, 2014</td>
</tr>
<tr>
<td>48</td>
<td>Sales Forecasts ($) for HPV Vaccines in the United Kingdom, 2012-2022</td>
</tr>
<tr>
<td>49</td>
<td>Key Events Impacting Sales for HPV Vaccines in the United Kingdom, 2012-2022</td>
</tr>
<tr>
<td>50</td>
<td>United Kingdom HPV Vaccine Market - Drivers and Barriers, 2014</td>
</tr>
<tr>
<td>51</td>
<td>Sales Forecasts ($) for HPV Vaccines in Japan, 2012-2022</td>
</tr>
<tr>
<td>52</td>
<td>Key Events Impacting Sales for HPV Vaccines in Japan, 2012-2022</td>
</tr>
<tr>
<td>53</td>
<td>Japan HPV Vaccine Market - Drivers and Barriers, 2014</td>
</tr>
<tr>
<td>54</td>
<td>Sales Forecasts ($) for HPV Vaccines in Australia, 2012-2022</td>
</tr>
<tr>
<td>55</td>
<td>Key Events Impacting Sales for HPV Vaccines in Australia, 2012-2022</td>
</tr>
<tr>
<td>56</td>
<td>Australia HPV Vaccine Market - Drivers and Barriers, 2013</td>
</tr>
<tr>
<td>57</td>
<td>Sales Forecasts ($) for HPV Vaccines in Canada, 2012-2022</td>
</tr>
<tr>
<td>58</td>
<td>Key Events Impacting Sales for HPV Vaccines in Canada, 2012-2022</td>
</tr>
<tr>
<td>59</td>
<td>Canada HPV Vaccine Market - Drivers and Barriers, 2014</td>
</tr>
<tr>
<td>60</td>
<td>Key Launch Dates</td>
</tr>
<tr>
<td>61</td>
<td>Key Patent Expiries</td>
</tr>
<tr>
<td>62</td>
<td>High-Prescribing Physicians (non-KOLs) Surveyed, By Country</td>
</tr>
</tbody>
</table>

1.2 List of Figures
Figure 1: Historical and Projected HPV Vaccination Coverage (%) in the United States among 12-Year-Old Females, 2007-2022
Figure 2: Historical and Projected HPV Vaccination Coverage (%) in France among 14-Year-Old Females, 2007-2022
Figure 3: Historical and Projected HPV Vaccination Coverage (%) in Germany among 17-Year-Old Females, 2009-2022
Figure 4: Historical and Projected HPV Vaccination Coverage (%) in Italy among 12-Year-Old Females, 2009-2022
Figure 5: Historical and Projected HPV Vaccination Coverage (%) in Spain among 14-Year-Old Females, 2008-2022
Figure 6: Historical and Projected HPV Vaccination Coverage (%) in the United Kingdom among 12-Year-Old Females, 2008-2022
Figure 7: Historical and Projected HPV Vaccination Coverage (%) in Japan among 16-Year-Old Females, 2012-2022
Figure 8: Historical and Projected HPV Vaccination Coverage (%) in Australia among 13-Year-Old Females, 2007-2022
Figure 9: Historical and Projected HPV Vaccination Coverage (%) in Canada among 12-Year-Old Females, 2007-2022
Figure 10: HPV Vaccines - Clinical Trials by Country, 2014
Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in HPV Vaccines, 2012-2022
Figure 12: Company Portfolio Gap Analysis in HPV Vaccines, 2012-2022
Figure 13: Global Sales for HPV Vaccines by Region, 2012-2022
Figure 14: Sales for HPV Vaccines in the US by Vaccine Class, 2012-2022
Figure 15: Sales for HPV Vaccines in France by Vaccine Class, 2012-2022
Figure 16: Sales for HPV Vaccines in Germany by Vaccine Class, 2012-2022
Figure 17: Sales for HPV Vaccines in Italy by Vaccine Class, 2012-2022
Figure 18: Sales for HPV Vaccines in Spain by Vaccine Class, 2012-2022
Figure 19: Sales for HPV Vaccines in the United Kingdom by Vaccine Class, 2012-2022
Figure 20: Sales for HPV Vaccines in Japan by Vaccine Class, 2012-2022
Figure 21: Sales for HPV Vaccines in Australia by Vaccine Class, 2012-2022
Figure 22: Sales for HPV Vaccines in Canada by Vaccine Class, 2012-2022

Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022
Web Address: http://www.researchandmarkets.com/reports/2870448/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 10995</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 32985</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 21990</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code: ____________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World